Critical Path for Parkinson’s Welcomes New Co-chairs Pagano, Gaetano

Critical Path for Parkinson’s mission is to serve as a leading international consortium convening diverse stakeholders to collectively advance data driven collaborative research aimed at accelerating drug development. The CPP co-director has a unique opportunity for broad visibility and to contribute to advancing regulatory science and encourage collaboration amongst all stakeholders. The benefits to the CPP co-director are many and include visibility and impact in shaping the future success of drug development as well as driving what is important to patients. We would like to welcome Dr. Gennaro Pagano, Group Leader and Expert Medical Director at F. Hoffman La Roche as our new Industry Co-Director. He has been a strong leader in CPP, and other collaborative initiatives aimed to partner with Dr. Pagano across many different CPP working groups and he was awarded the CPP data sharing pioneer award in 2022. CPP is grateful to be working with such a passionate dedicated leader with a focus on what is most important to people living with Parkinson’s.

Critical Path for Parkinson’s 3DT (digital drug development tool) program would like to welcome Dr. Laura Gaetano, Senior Director of Data Science in Neuroscience at Novartis as CPP’s Industry Co-Director. Dr. Laura Gaetano has been an enthusiastic supporter of digital health technologies as tools that can enhance drug development across disorders of the nervous system. She believes that the community of experts in consortia can expand the ability to leverage the full potential of digital tools and translating these into real benefits for people living with Parkinson’s. The mission of CPP’s 3DT initiative is to serve as a leading international consortium convening diverse stakeholders to collectively develop the regulatory maturity of digital health technologies in Parkinson’s trials using data driven solutions. The 3DT industry co-director has a unique opportunity for broad visibility and to contribute to advancing regulatory science and encourage collaboration amongst all stakeholders.